Specialty
Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

Photodynamic Therapy Then & Now: Current Concepts for Real-World Use

By: Mark R. Barakat, MD; Rishi Singh, MD

Webinar Credits: 1

Verteporfin for photodynamic therapy (PDT) has been approved for decades as a treatment for retinal disorders. Eye care professionals need to understand all the real-world clinical scenarios in which the use of PDT alone or in combination with anti-VEGF therapy can be a more efficacious treatment option than anti-VEGF monotherapy.
View this engaging webinar to gain insight into PDT treatment options as demonstrated with case examples presented by leading retina specialists.

Expiration Date: Friday, June 26, 2020
Release Date: June 26, 2019

Learning Objectives

Upon completion of this activity, participants will be better able to:

  • Summarize the clinical benefits of photodynamic therapy in patients with retinal disorders.
  • Design a treatment regimen based on a personalized medicine approach for patients who do not respond adequately to anti-vascular endothelial growth factor injections.
  • Identify methods for effective photodynamic therapy delivery in clinic settings, including dosing, infusion periods, and determination of treatment size.
  • Differentiate the benefits of half fluence PDT and full fluence PDT on a real-world population.

Accreditation and Designation Statement

Accreditation Statement
Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Evolve Medical Education LLC designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty and Disclosures

DISCLOSURE POLICY 
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Mark R. Barakat, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allegra, Alimera, Genentech, Novartis, and RegenXBio. Shareholder: Ohr, Oxurion.

Rishi Singh, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Carl Zeiss Meditec, Genentech, Novartis/Alcon and Regeneron Pharmaceuticals/Bayer. Grant/ Research Support: Apellis.

Editorial Support Disclosures, Erin K. Fletcher, MIT, director of compliance and education, Evolve; Susan Gallagher-Pecha, director of client services and project management, have no financial relationships with commercial interests. Jaya Kumar, MD, peer reviewer, has no financial relationships with commercial interests.

Pretest

  • a. 1b. 2c. 3d. 4e. 5

Video Resources

Next

Test

Instructions

Step 1 of 3

33%
  • AgreeNeutralDisagree
    Summarize the clinical benefits of PDT in patients with retinal disorders
    Design a treatment regimen based on a personalized medicine approach for patients who do not respond adequately to anti-VEGF injections
    Identify methods for effective PDT delivery in clinic settings, including dosing, infusion periods, and determination of treatment size
    Differentiate the benefits of half fluence PDT and full fluence PDT on a real-world population
Back